Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PROCEPT BioRobotics
Silicon Valley Bank Advisor Predicts 2022 Will Be Year For Healthtech, Massive Consolidation
SVB health care advisor Jonathan Norris anticipates more consolidation in devices ahead with many mid-cap public companies looking to acquire innovative technologies to grow, and pushing the “big guys to have to figure out how to move faster.”
In Vivo’s Deals Of The Year 2021: Cast Your Vote!
It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Procept BioRobotics Seeks $164M To Go Public
The company is selling 6,556,000 shares at $25 a share to support the commercialization of its AquaBeam robotic system for minimally invasive treatment of benign prostatic hyperplasia.
Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Surgical Equipment & Devices
- Minimally or Less Invasive
Diagnostic Imaging Equipment & Supplies
- Surgical Equipment & Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.